Balancing oversight

Last month, the linkurl:California Institute for Regenerative Medicine;http://www.cirm.ca.gov/ (CIRM) linkurl:pulled 3 of the 76 SEED grants;http://www.the-scientist.com/blog/display/56148/ it had given in one of its very first rounds of funding due to inadequate progress -- a 4% revocation rate. On the flip side, the linkurl:National Institutes of Health;http://www.nih.gov/ (NIH), which funds nearly 10,000 research grants each year, says it hardly ever pulls basic research grants. What's the ri

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share
Last month, the linkurl:California Institute for Regenerative Medicine;http://www.cirm.ca.gov/ (CIRM) linkurl:pulled 3 of the 76 SEED grants;http://www.the-scientist.com/blog/display/56148/ it had given in one of its very first rounds of funding due to inadequate progress -- a 4% revocation rate. On the flip side, the linkurl:National Institutes of Health;http://www.nih.gov/ (NIH), which funds nearly 10,000 research grants each year, says it hardly ever pulls basic research grants. What's the right balance of oversight between giving out free money and thwarting scientific creativity?
Image: Wikimedia commons
On the one hand, science can be unpredictable -- adjusting to the curveballs an experiment may throw at an investigator is "how most discoveries are made, [and] we wouldn't want to squelch that creativity by [excessively] overseeing grants," said linkurl:Stuart Lipton;http://www.burnham.org/default.asp?contentID=242 of the Burnham Institute for Medical Research. "On the other hand, [the NIH] wants to make sure you do the work that's in the general purvey to what you proposed." The NIH monitors grant recipients via a required annual progress report for each grant they award, called a "non-competing continuation progress report." In order to receive the next year's money, investigators must have them approved by their program directors, who each oversee anywhere from 50 to 300 grants at a given time. Robert Finkelstein, associate director for extramural research at linkurl:National Institute of Neurological Disorders and Stroke;http://www.ninds.nih.gov/ (NINDS), could not think of any research project grants (e.g., R01s) that had been terminated by his institute in the last several years. "It's really pretty incredibly rare that we do this," Finkelstein said. Should the NIH have a stronger hand in the projects it funds? This question, not surprisingly, evoked mixed responses from the research community. The NIH's lax oversight does appear to open the door to researchers to use the funds for something other than what they proposed in their grant application, said linkurl:Andrea Elberger;http://www.utmem.edu/neuroscience/faculty/A_Elberger.php of the University of Tennessee Health Science Center. "The majority of us do what we're supposed to do and do it by the rules, but there are people who game the system and for those people it is easy to get away with it." Elberger recalled an incident she knew of in which, by the time the award was granted, the investigator had already determined that the proposed experiment wasn't going to work and decided to do something completely unrelated. To avoid questions, the investigator simply resubmitted preliminary data, "saying the experiment didn't work," Elberger said. "It was quite a successful ploy," she added. "They never got caught and they've become a very successful person in what they're doing. If oversight didn't catch that, it won't catch anything." Other stories reveal a less extreme, but perhaps more common, game -- using a grant for one thing to generate preliminary data for something else, in order to obtain another round of funding. Because a successful NIH grant application requires preliminary data, "the money that you're getting for [a particular] grant, you're using to generate preliminary data of the next grant," said David Adams of linkurl:Duke University School of Medicine.;http://medicine.duke.edu/modules/dom_welcome/index.php?id=1 "The people that have gotten into this continuity [and] have this system going [are] always publishing papers." This may be common, but would the NIH call it kosher? "While there is flexibility within the grant mechanism to explore new avenues of research within the general aims of the funded grant," project director Neil Buckholtz of the linkurl:National Institute on Aging;http://www.nia.nih.gov/ wrote in an email to The Scientist, "the investigators should not go into totally different areas of research using funds from the current grant." Such stories, though, demonstrate a flexibility of the NIH system that many scientists still feel is important to productive science. "Deep down I believe that scientists should be allowed to do whatever they want [within reason]," linkurl:Nejat Düzgünes;http://dental.pacific.edu/Faculty_and_Research/Department_Chairs/Microbiology_Chair.html of the University of the Pacific said. "We're at a certain stage in science [that] we really cannot tell where the science can go and what experiments the investigator needs to be doing 2 years or 4 years or 5 years from now. This is the way science is. Scrutinizing grantees would not be very productive." That's fine, some researchers say, but it's inconsistent with how the grants are awarded in the first place. "The actual review process absolutely doesn't work that way," Elberger said. To the contrary, "experienced scientists are asked to provide ridiculous amounts of detail" in their grant applications, regarding such things as methodology that are likely to change between the time the application is written and the time it is awarded. Thus, while the annual progress reports appear to be more of a bookkeeping policy -- only occasionally requiring follow-up and hardly ever resulting in grant termination -- the process of applying for the grant in the first place requires painstaking time and effort. "Why make us write all this information out and then let people get away with whatever they want?" said Elberger. "Either trust us or don't." "If you are going to spend so much [time] scrutinizing [the initial application] -- [and] making life so miserable for every scientist -- then you might as well scrutinize the grant afterwards," Düzgünes agreed. "[Otherwise] it doesn't make sense to be doing the first scrutiny." Even if there was a consensus that the NIH should tighten up their oversight, "I think it would be very tough to do," said linkurl:David Kaplan;http://www.case.edu/med/pathology/faculty/kaplan.html of Case Western Reserve University in Ohio. "The man power [it would require] would be extraordinary. We're talking about hours of analysis of what [the researchers] have done, what the literature is, what their results are, [and] what's reasonable. It must be an incredible amount of time." With nearly 10,000 research grants per year, the shear volume of grantees the NIH has at any given time prohibits any substantial level of oversight, Kaplan said. "I don't think there's any easy answer for them to do it differently."
**__Related stories:__***linkurl:Wanted: Records of revoked grants;http://www.the-scientist.com/blog/display/57088/
[20th January 2010]*linkurl:When does oversight overstep?;http://www.the-scientist.com/blog/display/56148/
[16th November 2009]*linkurl:NIH finally takes on conflicts;http://www.the-scientist.com/blog/display/55685/
[11th May 2009]*linkurl:How to spend the NIH stimulus;http://www.the-scientist.com/blog/display/55413/
[11th February 2009]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo